NCT00093132View on ClinicalTrials.gov

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

February 28, 2009

Conditions
Carcinoma, Non-small Cell LungLung Cancer
Interventions
DRUG

Satraplatin

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

Trial Locations (1)

75390

Southwestern Medical Center, Dallas

Sponsors

Lead Sponsor

Agennix
All Listed Sponsors
lead

Agennix

INDUSTRY

NCT00093132 - Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy | Biotech Hunter | Biotech Hunter